Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Peter Oppelt et al.|Clinical Cancer Research|2020Cited by 368
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaChristopher D. Carey, Scott J. Rodig, Daniel Gusenleitner et al.|Blood|2017Cited by 332
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating LymphocytesVishwajith Sridharan, Jonathan D. Schoenfeld, Evisa Gjini et al.|Cancer Immunology Research|2016Cited by 101
FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissuesAlba Font‐Tello, Henry W. Long, Nikolas Kesten et al.|Nature Protocols|2020Cited by 36
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Katie M. Campbell et al.|Clinical Cancer Research|2021Cited by 14